Analyzing TranS1 (OTCMKTS:BAXSQ) and Bioventus (NASDAQ:BVS)

TranS1 (OTCMKTS:BAXSQ) and Bioventus (NASDAQ:BVS) are both manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Insider & Institutional Ownership

62.9% of Bioventus shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares TranS1 and Bioventus”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TranS1	N/A	N/A	N/A	N/A	N/A
Bioventus	$573.28 million	0.94	-$33.54 million	N/A	N/A

TranS1 has higher earnings, but lower revenue than Bioventus.

Profitability

This table compares TranS1 and Bioventus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TranS1	N/A	N/A	N/A
Bioventus	-0.03%	23.04%	6.04%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for TranS1 and Bioventus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TranS1	0	0	0	0	0.00
Bioventus	1	0	0	0	1.00

Given TranS1’s higher possible upside, equities analysts clearly believe TranS1 is more favorable than Bioventus.

Summary

Bioventus beats TranS1 on 6 of the 8 factors compared between the two stocks.

About TranS1

Baxano Surgical, Inc., formerly Baxano Inc. is a medical device company. The Company is focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. The Company markets the AxiaLIF pre-sacral access and interbody fusion system for single and two level lower lumbar fusion, the VEO lateral access and interbody fusion system, the iO-Flex set of flexible instruments used by surgeons during spinal decompression procedures, and the iO-Tome instrument for rapid and precise removal of bone, specifically the facet joints, a technique which is commonly performed in spinal fusion procedures. The Company’s other products include: Vectre facet screw system, Bi-Ostetic bone void filler, bowel retractors, discectomy tools, and a bone graft harvesting system that can be used to extract bone graft from the patient’s hip for use in fusion procedures.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.